ZYBERNO
Stock Report
Updated Sep 1, 2026

GERON CORP (GERN)

Healthcare • NASDAQ

$1.51

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
17.0/100
POOR BUSINESS
GERON CORP (GERN) scores 17/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-29.3%)
Debt-to-Equity (Solvency Risk):AVERAGE (0.77x)
Operating Margin (Operational Efficiency):CRITICAL (-25.2%)
Return on Capital (Capital Efficiency):CRITICAL (-13.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

GERON CORP (GERN) stock report — Zyberno Score 17/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, GERN generated -$219.08M in Owner Earnings. Capital was deployed as follows: $680.00K invested in capital expenditures. Reinvestment rate: -1.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.51
Market Cap:$1.01B

Valuation Multiples (3)

P/B Ratio:4.60x
P/S Ratio:4.89x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.07B

Price Action & Momentum (3)

Momentum Percentile:29 / 100
% of 52-Week High:75.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-12.3%
Reinvestment Rate:-1.0%
Fundamental Growth Rate (g):0.1%

Margin Analysis (3)

Operating Margin Ttm:-25.2%
Net Margin Ttm:-32.9%
Ebitda Margin:-24.9%

TTM Performance (2)

Operating Margin Ttm:-25.2%
Net Margin Ttm:-32.9%

Yield Metrics (2)

Earnings Yield:-$7.28
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-220.0%
Latest Earnings Filed:2026-08-05

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):100.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:6.92x
Quick Ratio:5.16x
Cash Ratio:0.89x

Leverage Analysis (3)

Debt To Equity Ttm:0.77x
Debt-to-Equity Ratio:0.77x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-6.41x
Times Interest Earned:-6.41

Capital Structure (4)

Working Capital:416,008,000.00
Cash And Cash Equivalents:62,643,000.00
Long Term Debt:$120.13M
Net Debt:$69.45M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $205.58M
Linear Growth: 100.0%
📊 Click to view full GERN Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$51.77M

Bottom Line Performance (3)

-$67.61M
Income Before Tax:-$83.43M
Ebitda Ttm:-51,288,000.00

Operating Expenses (5)

Operating Expenses:256,324,000.00
R And D Expense:71,605,000.00
Sga Expense:154,957,000.00
Income Tax Expense:$75.00K
Interest Expense:30,234,000.00

Expense Ratios (3)

R And D To Revenue Percentage:124.6%
Sga To Revenue Percentage:269.6%
Ebitda Margin:-24.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$519.01M
Current Assets:$486.34M
Ppe Net:1,089,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:300,395,000.00
Current Liabilities:70,331,000.00
Long Term Debt:$120.13M
Short Term Debt:$11.97M

Equity & Capital (3)

Equity:$218.61M
Retained Earnings:-$1.88B
Common Stock:642,000.00

Working Capital Items (3)

Accounts Receivable:51,640,000.00
Inventory:123,604,000.00
Accounts Payable:30,715,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:4,913,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$125.96M-$126.64M

Investment Activities (2)

Investing Cash Flow:$51.86M
Capital Expenditures Ttm:680,000.00

Financing Activities (3)

Financing Cash Flow:$2.43M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:477,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.11
-$0.11
Earnings Per Share Ttm:-$0.10

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.31
Operating Cash Flow Per Share:-$0.25

Book Value & Capital (2)

Book Value Per Share:$0.33
Cash Per Share:0.09

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.38x
Working Capital Turnover Ttm:0.49x

Receivables Management (2)

Receivables Turnover Ttm:3.98x
Days Sales Outstanding Ttm:91.68

Inventory Management (2)

Inventory Turnover Ttm:1.66x
Days Inventory Outstanding Ttm:219.45

Payables & Cash Cycle (2)

Days Payable Outstanding:54.53
Cash Conversion Cycle:256.61
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:35.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$219.08M

Damodaran Growth Analysis (2)

Reinvestment Rate:-1.0%
Fundamental Growth Rate (g):0.1%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):100.0%

Other Growth Rates (1)

Book Value Growth Rate (Linear):13.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:GERN
Company Name:GERON CORP
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:665.87M
Shares Outstanding Basic:670.70K
Shares Outstanding Diluted:670.70K

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 13:08:26 UTC
Data Timestamp:2026-09-01T13:08:26.954735
Scroll to Top